ArticleCancers2023

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab-Bevacizumab in Hepatocellular Carcinoma.

Catia Giovannini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.